Dr. Agarwal's Eye Hospital Limited has notified the stock exchanges of a forthcoming Board of Directors meeting, scheduled for Wednesday, May 20, 2026. The intimation has been filed pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will take up key financial and governance matters pertaining to the concluded financial year.

Board Meeting Agenda

The board meeting has been convened to consider and approve the audited financial results of the company for the quarter and year ended March 31, 2026. In addition to the financial results, the board will also deliberate on the recommendation of a final dividend, if any, for the Financial Year 2025-26. The following table summarises the key details of the scheduled meeting:

Trading Window Closure

In line with the company's Code of Internal Procedures and Conduct for Prohibition of Insider Trading, the Trading Window will remain closed until 48 hours after the announcement of the aforementioned financial results. This measure is consistent with standard regulatory practice to prevent insider trading during periods when price-sensitive information is pending disclosure.

The official corporate announcement is also available on the company's website at https://dragarwals.co.in/dr-agarwals-eye-hospital/#corporate-announcement . The intimation was signed by Meenakshi Jayaraman, Company Secretary and Compliance Officer, on May 14, 2026.

The Hon'ble National Company Law Tribunal (NCLT), Chennai Bench, has allowed the joint First Motion Application filed by Dr. Agarwal's Health Care Limited (AHCL) and Dr. Agarwal's Eye Hospital Limited (AEHL), marking a significant procedural milestone in the proposed Scheme of amalgamation between the two companies. Both companies have independently disclosed the development to the stock exchange under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The hearing was held on May 05, 2026, and the formal written Order was uploaded on the NCLT website on May 11, 2026.

NCLT Order: Key Details

The Order directs AHCL and AEHL to convene their respective meetings of shareholders and creditors for the purpose of considering and, if thought fit, approving — with or without modification(s) — the amalgamation embodied in the Scheme. The following key details pertain to the meetings as directed by the NCLT:

Background and Prior Disclosures

The disclosures reference prior communications made to the stock exchange, including letters dated February 17, 2026, and August 27, 2025, indicating that the amalgamation process has been underway for a considerable period. The Scheme involves the amalgamation of AHCL and AEHL along with their respective shareholders and creditors, under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, read with the rules and/or regulations framed thereunder.

Next Steps and Pending Approvals

The certified copy of the NCLT Order is currently awaited and will be made available on the websites of both AHCL and AEHL promptly upon its receipt. Both companies have stated that other relevant details pertaining to the aforementioned meetings, along with copies of the notices, shall be submitted to the stock exchange in due course. Importantly, the Scheme remains subject to the receipt of all necessary statutory and regulatory approvals as may be required under applicable laws.

The disclosure on behalf of Dr. Agarwal's Health Care Limited was signed by Thanikainathan Arumugam, Company Secretary and Compliance Officer, and was digitally authenticated on May 11, 2026. The corresponding disclosure on behalf of Dr. Agarwal's Eye Hospital Limited was signed by Meenakshi Jayaraman, Company Secretary and Compliance Officer, also on May 11, 2026.